Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment
By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine...
Source: marketwatch.com